Eli Lilly and Company $LLY Shares Sold by Gordian Capital Singapore Pte Ltd

Key Points

• Gordian Capital Singapore Pte Ltd reduced its holdings in Eli Lilly and Company by 75.6%, now owning 315 shares worth $260,000 according to its latest SEC filing.
• Several institutional investors significantly increased their stakes in Eli Lilly during the first quarter, with PNC Financial Services Group lifting its position by 97.5% and GAMMA Investing LLC by an astonishing 103,831.6%.
• Eli Lilly reported impressive quarterly earnings, exceeding expectations with a $6.31 EPS and a revenue of $15.56 billion, which was 37.6% higher year-over-year.

Gordian Capital Singapore Pte Ltd lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 75.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 315 shares of the company's stock after selling 975 shares during the quarter. Gordian Capital Singapore Pte Ltd's holdings in Eli Lilly and Company were worth $260,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Corient IA LLC acquired a new position in Eli Lilly and Company in the first quarter valued at about $570,000. LS Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after buying an additional 40 shares during the period. Prism Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the 1st quarter valued at $207,000. Hemington Wealth Management raised its holdings in shares of Eli Lilly and Company by 14.4% in the 1st quarter. Hemington Wealth Management now owns 985 shares of the company's stock valued at $813,000 after buying an additional 124 shares during the period. Finally, Bfsg LLC raised its holdings in shares of Eli Lilly and Company by 1.4% in the 1st quarter. Bfsg LLC now owns 2,959 shares of the company's stock valued at $2,444,000 after buying an additional 42 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. UBS Group cut their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Finally, Guggenheim cut their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average target price of $950.17.

Insider Activity

In related news, CEO David A. Ricks acquired 1,632 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares of the company's stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last quarter. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $0.45 during trading hours on Friday, reaching $732.41. The stock had a trading volume of 2,548,350 shares, compared to its average volume of 6,895,566. The firm has a market cap of $693.20 billion, a price-to-earnings ratio of 47.87, a PEG ratio of 1.02 and a beta of 0.44. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $969.65. The firm has a 50-day moving average of $748.68 and a 200-day moving average of $785.49.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.